达沙替尼诱导肺动脉高压的长期结局:一项基于人群的研究
该研究从法国肺动脉高压注册登记中纳入21例经右心导管确诊的达沙替尼诱导肺动脉高压(PAH)患者,中位随访24个月。停用达沙替尼后,功能分级、6分钟步行距离及血流动力学均显著改善,但37%的患者PAH持续存在,4例死亡。
要点
- 达沙替尼诱导的PAH在停药后常改善,但37%患者持续存在。
- 停药后NYHA功能分级、6分钟步行距离及血流动力学均显著改善。
- 需对达沙替尼诱导的PAH患者进行系统性长期随访。
核心结论
- 达沙替尼诱导的PAH在停药后常改善,但超过三分之一患者PAH持续存在,系统性随访至关重要。
研究设计与样本
- 基于法国肺动脉高压注册登记的人群研究,纳入21例经右心导管确诊的达沙替尼诱导PAH患者,中位随访24个月(范围1-81个月)。
主要发现
- 中位年龄52岁,女性15例(71%)。
- 19例因慢性髓性白血病接受达沙替尼,诊断PAH前中位用药42个月(范围8-74个月)。
- 10例接受检测的患者中未发现BMPR2突变。
- 随访期间4例死亡。
- NYHA III/IV级比例从76%降至10%(p<0.01),6分钟步行距离中位值从306米(范围0-660)改善至430米(范围165-635,p<0.01)。
临床怎么用
- 对达沙替尼诱导的PAH患者应停用达沙替尼并进行系统性长期随访。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
This study aimed to describe the long-term outcomes of pulmonary arterial hypertension (PAH) induced by dasatinib.21 incident, right heart catheterisation-confirmed cases of dasatinib-induced PAH were identified from the French Pulmonary Hypertension Registry. Clinical and haemodynamic variables were compared from baseline to last follow-up (median (range) 24 (1-81) months).Median age was 52 years and 15 patients were female (71%). 19 patients received dasatinib for chronic myelogenous leukaemia for a median (range) duration of 42 (8-74) months before PAH diagnosis. No bone morphogenic protein receptor-2 (BMPR2) mutations were found in the 10 patients tested. Dasatinib was uniformly discontinued and 11 patients received PAH medications. Four patients died during follow-up. New York Heart Association functional class improved from 76% in class III/IV to 90% in class I/II (p<0.01). Median (range) 6-min walk distance improved from 306 (0-660) to 430 (165-635) m (p<0.01). Median (range) mean pulmonary arterial pressure improved from 45 (30-70) to 26 (17-50) mmHg (p<0.01) and pulmonary vascular resistance from 6.1 (3.2-27.3) to 2.6 (1.2-5.9) Wood units (p<0.01). Patients treated with PAH medications had worse baseline haemodynamics but similar long-term outcomes to untreated patients. PAH persisted in 37% of patients.Dasatinib-induced PAH frequently improves after discontinuation but persisted in over one-third of patients, therefore systematic follow-up is essential.
引用
- Weatherald J, Chaumais MC, Savale L, et al. Long-term outcomes of dasatinib-induced pulmonary arterial hypertension: a population-based study. Eur Respir J. 2017. PMID: 28751413. doi:10.1183/13993003.00217-2017
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。